跳至主要内容
临床试验/EUCTR2006-004432-70-IT
EUCTR2006-004432-70-IT进行中(未招募)不适用

A multicenter phase II study to evaluate the safety, tolerability and efficacy of caspofungin as prophylactic treatment of invasive fungal infections in patients with acute leukemia undergoing induction chemotherapy - ProFIL-C

AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA0 个研究点开始时间: 2006年11月10日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - all patients with a diagnosis af acute leukemia who are enrolled in the clinical protocols of NILG for acute leukemia at diagnosis - age 18 - written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - presence of clinical, radiological or microbiological evidence of invasive fungal infection at enrollment - concomitant use of systemic parenteral or oral antifungal agents - hypersensitivity, or any serious reaction to echinocandin - pregnancy or breast-feeding - acute hepatitis or moderate/severe hepatic insufficiency of any cause; - recent prior use of caspofungin - concomitant use of rifampin, carbamazepine, phenytoin, fenobarbital, or other inducers of CYP450 enzymes

研究者

发起方
AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA

相似试验